Q3 2022 Albireo Pharma Inc Earnings Call

Yeah.

Good afternoon, and welcome to the Alberta, <unk> Pharma third quarter 2022 earnings call. At this time all participants are in a listen only mode. A question and answer session will follow the formal presentation.

If anyone should require operator assistance during the call. Please press Star then zero on your telephone keypad. Please note that this conference is being recorded I will now turn the call over to your host Hunt fits them managing director of lifestyle advisors. Thank you you may begin.

Thank you operator.

Afternoon, <unk> issued a press release, highlighting its recent business accomplishments and financial results for the third quarter ended September 32022 press.

Press release is accessible via the company's website at Albert <unk> pharma dotcom.

Before proceeding we would like to note that the management's comments today may include forward looking statements regarding the company's plans and expectations. These statements are being made under the private Securities Litigation Reform Act of 1995, and they are subject to various risks and uncertainties actual results may differ materially due to various.

Important factors, including those described in the risk factors section of the company's most recent Form 10-K and subsequent SEC filings. These.

These filings can be accessed from the investors section at Albemarle pharma dot com or on the SEC's website any forward looking statements represent our views as of today November 8th 2022 and should not be relied upon as representing our views as of any subsequent dates we undertake no obligation to.

Update these statements.

Now it is my pleasure to turn the call over to Ron Cooper, Albert <unk>, President and Chief Executive Officer Ron.

Well thanks, Tom.

Thank you all for joining us. This afternoon with me today are Dr. Jan Madsen, Chief Scientific officer, and head of R&D, Pamela Stephenson and our Chief commercial officer, and Simon Harford, Our Chief Financial Officer.

It's been another significant quarter for Albarello as we continue to develop our lead product build <unk> to reach its full potential we're moving fast to strengthen the value and build they both on the clinical evidence front and on the commercial front revenues have accelerated this quarter.

Exciting as we anticipate gaining access to more patients in additional diseases.

We're also excited to present, new top quality data.

At the Aes will be deliberate meeting this past weekend.

Let me turn it over to John to give you an update on the data in our studies yawn.

Thanks, Tom we had a very rich weekend at the ASD meeting with three oral presentations, including two late breakers, that's exposed to as well.

I would specifically like to draw your attention to three important clinical study achievements.

Starting with disease modification of native liver survival, we have always believed that they would be a drug that would improve both the symptoms of called a static liver diseases as well as modify the natural course of the diseases.

As you can appreciate it takes a little bit of time to generate data for the latter, but we are moving with urgency and the first dataset is now available.

In scientific sessions, we presented in an oral session data demonstrating the appeal of a improved native liver survival in patients with P. If at all.

Full data analysis show that piece pick patients who responded to build a remained labour transplant free for up to three years.

Decrease in serum bile acids at six months of treatment was strongly associated with native liver survival with serum bile acid responders versus non responders with a P value of 0.005.

The sponsors also had mean improvements in liver function parameters.

All perfect bile acid responders, and all pruritus wonders remained transplant free for up to three years.

In addition, there was a late breaking oral presentation, demonstrating the appeal to be restored biliary bile acid flow and was selected by a S. L. D. For inclusion is a key presentation in the best of the liver meeting independently as he kept pathology category.

This is just the first step in demonstrating native liver survival with pill, a day and we anticipate providing additional data in the near future.

In addition, we present the data at the <unk> annual meeting last month, which supports treating children as early in the disease of possible people with mild pruritus could result in greater efficacy episode.

Native liver.

Now the great clinical achievement is the third we announced topline data for this phase III study in other deals in less than a month ago and the R&D team has worked diligently to be able to submit the updated dataset to as of the in record time.

As well our regulatory team is working fast to file submissions in the U S and Europe trying to beat the record we set out with our <unk> submission.

Our third date that was accepted by age will be as a late breaking oral presentation and was selected as a key presentation in the best of the liver meeting independent Jesse kept all the category there.

The response from the medical community has been enthusiastic and very positive for the first time. It has been demonstrated in our phase III study, that's and I bet inhibitor can work across the two most prominent genetic sites in <unk> syndrome, and in a wider age range of patients to achieve the.

I'll be brief pruritus reduced bile acids, and improved sleep with low drug related diarrhea rate.

Drug related diarrhea was similar to what we have saw with the pet food studies.

Five 9% in placebo and 11, 4% in the Bill that group.

Overall treatment about diarrhea rates was also low with placebo being five 9% and build a group at 28, 6%.

With over 90% of patients being pruritus responders doing this study is defined as at least a one point drop at any time point, we can provide lilly relief to so many patients at the load therapeutic dose of bill way without having to cope with hydro <unk> levels.

Finally, I'm proud of our R&D organization for their hard work and the termination to fully enroll the both phase III studies and build our tricia According to our public guidance.

We exceeded our target with two under five children versus 200, we're now enrolled into the largest global phase III, a drastic called static trial ever conducted across 58 sites around the world and during the Covid pandemic.

We have had extensive discussions with regulatory bodies and decided to try to meet the approval requirements.

<unk> is the most common the drastic liver disease and given our recent success with our build their phase III studies in PC and I'll, let Jill syndrome, we feel confident of a positive outcome and look forward to a topline data readout in 2024.

So to conclude I'm pleased to share with you new evidenced the appeal they can improve native liver survival in pediatric patients is effective in <unk> patients and I'm looking forward to supporting build data in <unk> patients.

Do you love.

Great. Thanks, Jan for the scientific update.

<unk> clearly differentiate bill pay is the best in class I bet inhibitor.

<unk> is the only I bet inhibitor to show efficacy across all types, including <unk> pick one in long term studies.

So unlike other ipads bellway has a low therapeutic dose is given once a day and easy to administer capsules or sprinkles that can be combined with food or liquids.

<unk> has demonstrated a low drug related diarrhea rate, that's only a little above placebo in two placebo controlled trials.

We're evaluating <unk> in phase III studies in P. Fig, Jill syndrome, and now a third one in biliary atresia.

With biliary atresia, the opportunity is roughly the size of <unk> and Alan <unk> combined.

We expect <unk> to be first to market with a positive outcome of the bolt study.

What does all of this means it means that we have a product that is approved for perfect convenient for patients with excellent tolerability addressing a broader patient population across many mutation types.

<unk> clinical data supporting its potential approval in <unk> syndrome.

We're already seeing this in the building and launching <unk> with an excellent Q3, So let me turn it over to Pamela to provide more details on the quarter envelope.

Thanks, Ron and good afternoon, everyone. We are delighted with fill rates ongoing global watch the first and only FDA approved medication for patients with <unk> benefiting more patients around the world.

Today I'll share further color until <unk>, seven 5 million net product sales in Q3, and what we're seeing on the commercial front.

Now have a total of 270 bill they patients, which is 25 more patients compared to the previous quarter.

We increased the number of reimbursed patients by more than 25% with 27, new patients, giving a total of 126.

These patients account for the $7 5 million in revenue and we have another 144 patients 77 pending reimbursement in 67 rollover patients who are on the drug war on drugs that we expect to be revenue generating in the future.

Revenues are continuing to trend up and we are starting to see the annuity we mentioned last quarter.

Oh wait variability is normalizing over time as expected the discontinuation rate is in line with expectations and rates observed with comparable products in rare disease overall.

Overall prescribers see the benefits of our treatment its efficacy and its advantages with convenience for caregivers and families with a once daily easy administration of the drug and its favorable tolerability profile.

I'll start with the international business, especially in Europe , where we are excelling on delivering on our promise to make build a global product and the HCP believe in this product and see that the real world use is in line or even better than what was seen in clinical trials.

Furthermore, our speed and execution on pricing and reimbursement demand generation and scientific exchange has been optimal and again you see it translate into patient capture in revenue growth we.

We are continuing to grow in the European market with Bill <unk> reimbursement confirmed in five European markets, Germany, The U K, Italy, Belgium, and recently in France.

This strong platform will serve us well as we plan to launch our product in allergy all syndrome and eventually in biliary atresia.

Still they continues to receive high clinical ratings from European Payor Health technology assessments based on our phase III trial results.

<unk>, it's unique approach early rapid and sustained benefit as well as favorable tolerability.

H C piece in Europe believe and built a as a liver drug and our understanding its potential to preserve native liver as demonstrated by our disease modification label in Europe , and our long term data just presented it as all day.

Let's take a closer look at the U S. We are seeing an increased demand in the U S. Mostly because of our relentless work in the field. We continue to steadily increase the number of unique prescribers each quarter since launch, adding 13, new <unk> in Q3 to bring our total unique prescribers.

Scriber 286.

Had the most success in the accounts, where hcp's understand how bill they can treat a symptom of the underlying liver disease and act with urgency to treat their perfect patients.

As a result, we are dialing up and deploy strong urgency to treat disease education programs and aligning our U S sales force and MSL resources to accounts, where we need to help clinicians understand the importance of treating pruritus immediately even mild cases.

This additional resource allocation should help continue to accelerate our expanding U S prescriber base.

Since our launch of Pizza continues to progress the company is preparing for another bill. They launch this time for allergy all central following the impressive phase III data, we are excited to take learnings and opportunities from the pizza launch the treating physicians are the same in both indications and the benefits they are seeing for pubic patients.

Should translate into prescriptions and allergy L central and eventually in biliary atresia and.

In Europe , we have had ongoing meetings in dialogue with all the major payer and reimbursement authorities, which gives us a leg up for what to anticipate analogy L. <unk>.

Furthermore, the total global market opportunity is larger than <unk>, and we believe that every 10 points of market share, it's worth somewhere between $50 million to a $100 million, we expect to be launching in most European countries at a similar time as the other I bet inhibitor given our already.

Strong price and reimbursement position and in the U S. Even as a second entrant, we expect to capture a valuable market share.

I will close by saying that the real life experience for physicians and patients across many different types of <unk> patients has been overwhelmingly positive and we are looking forward to being able to gain access to more patients with analogy all indication now.

Now I'll hand, the call over to Simon to cover our financial review Simon.

Thank you Pamela let me summarize our financial results for the third quarter of 2022 Bill.

It will take global net product revenue was $7 $5 million in the quarter up from $1 1 million in the same quarter last year.

<unk> revenue was $4 $1 million and international revenue was $3 4 million.

As we look forward to the end of the year, there will be an impact on Q4 international sales as we are now outside of the 12 months free pricing period in Germany, we.

We are very pleased with the revenue in Q3, but for the time being a leaving 2020 to build their revenue guidance at $24 million.

Royalty revenue was $2 3 million for the third quarter of 2022, compared with $2 6 million in the same period of 2021, resulting in net to decrease of $3 million. The decrease relates to estimated royalty revenue, which is passed on to healthcare royalty partners.

Cost of product revenue was $6 million for the third quarter of 2022, compared with <unk> 4 million in the prior quarter.

Following approval of build a certain manufacturing and quality head count costs are now included in cost of product revenue.

No material costs is materials related to current products sold were expensed prior to approval.

Research and development expenses were $23 3 million for the three months ended September 32022, compared with $21 1 million for the same period in 2021, an increase of $2 $2 million. The increase in research and development expenses was principally due to.

Clinical program activities.

Selling general and administrative expenses were $20 6 million for the third quarter compared to $17 6 million last year in Q3, an increase of $3 million.

The increase is attributable to personnel and related expenses as we continue to increase our head count and commercialization activities related to bill pay including our sales force and support for global expansion efforts.

Net loss for the third quarter of 2022 was $37 8 million or a loss of $1 92 per share compared to net income of $57 1 million or income of $2 90 per share on a fully diluted basis for the third quarter of 2021.

Income in Q3 dollars 21 was due to the net proceeds from the one time sale of the priority review voucher for Bill pay.

We entered in September into a royalty monetization agreement with cigar healthcare partners for a total net amount of $111 6 million Upfronts in return for a mid single digit average royalty rate on build a global annual net revenues, if all three indications or a P.

These additional resources provide us with the means to further develop built <unk> into a billion dollar product for the treatment of additional red Cola static liver diseases. The agreement is treated as debt for financial reporting purposes. As a result of the net proceeds from the upfront fee are recorded on the <unk>.

Alan sheets, rather than the income statement.

The only impact to the income statement is related to the revenue interest liability under interest expense.

The company had cash cash equivalents and restricted cash of $272.

$5 million as of September 30th 2022.

The company expects this total cash to be sufficient to extend our runway beyond the at least the topline data readout.

<unk> study in biliary atresia, and 2024 based on current revenue and expense projections.

Let me turn it back to Ron for closing remarks.

Thank you Simon.

With <unk>, we have a product with the best in class profile and stellar clinical data.

The company in a strong place with total bill B patients, increasing a strong third quarter sales solid cash position two successful phase III studies in <unk> syndrome, and another ongoing phase III and Billary atresia now fully enrolled.

Continue to be on a steady pace to drive our aspiration of making building a billion dollar drug in the second half of the decade.

Key for us to take bill rate from a <unk> medicine to a leading pediatric cholesteric liver disease drug.

We continue to progress our early assets in adult liver disease with <unk> 907, and 803, <unk> <unk>, two which will go into phase II and phase one trials respectively.

This strong portfolio and financial position, we have a tremendous opportunity and we'll remain focused on our growth drivers.

We thank everybody for joining us we're pleased to open the call now for Q&A operator.

Thank you we will now begin the question and answer session to join the question queue. You May Press Star then one on your telephone keypad, you'll hear a tone acknowledging your request if you.

We're using a speakerphone please pick up your handset before pressing any keys to withdraw your question. Please press Star then two we will pause for a moment as callers join the queue.

Our first question comes from Ian Yang of Jefferies. Please go ahead.

Hi, This is nolan on for you and thank you very much for taking our question. We have one on biliary atresia. Please so we've heard that most pediatric patients get a liver transplant.

As you know and only curative option.

Is it reasonable to assume that the way bill pay with the east to bridge the gap to liver transplant. Thank you.

Yeah.

Thanks now the first first we're pretty excited about getting the ball trial fully enrolled this is the largest study in pediatric cholestasis. There right now when you think about these children with biliary atresia. It really is it's really terrible. So these films right because they have their baby.

They have this kasai procedure and then the parents lasts for what treatments are available and there are no treatments available.

So the only thing that can really look.

Look towards is sometime in the future a liver transplant.

What we're hoping with bill days that we bring hope to those families and those children by changing that course, right. So either delaying a transplant of the child was even healthier or potentially even preventing that that transplant. So we're looking forward to getting that data in 2024.

Thank you.

Our next question comes from Brian <unk> of Baird. Please go ahead.

Hey, good afternoon, guys. Thanks for taking my questions just wanted to kind of look at the numbers that you have in your corporate back in terms of Solvay patients reimbursed patients. So I'm just wondering if I kind of like look at the end.

Coming out of each of the last quarters sort of do a back of the envelope calculation against the reimbursed patients.

Sort of the expected net launch price it sort of matches up with what the next corner. So I guess, you know if I kind of step wise looking at five and a half seven and a half it would kind of imply like nine and a half per.

Fourth quarter based on the Entre <unk> Rolling out this quarter can you help us understand is that sort of the right way to think about what those reimbursed patients represent in terms of protecting revenue.

So what I would say too Brian is obviously, if theres not a direct correlation it is more than that.

Indicator of direction of travel in trends for future revenue on the basis that as we've discussed many times you have everything from six months our children all the way up to sort of teenagers, which have quite a widespread in terms of.

Individual revenue, particularly at this point still in the launch so that will be some variability from <unk>.

Time to time, but suddenly the trend is that to help you understand that we're going in an upward direction overtime.

Great and then maybe just a follow up to your point on sort of that that variability as you get more patient sort of under <unk>.

Reimbursement.

See more consistent net pricing per patient.

And sort of that Choppiness that we saw over the first couple of quarters do you think we're at a point, where it's sort of a more reliable average.

So I think it's becoming more reliable because ultimately you're right sort of the critical mass.

Time should sort of average things out to a greater extent, but that's not to say that could still be some bumps along the road.

From pumping this is the way I should maybe put it in terms of rapid new for a few quarters together.

Got it. Thanks, that's helpful I'll hop back in the queue.

Yes, thank you for the questions Brett.

Implicitly if you look at the value between the child versus a teenager in adult it's really 10 times the difference right. So when Simon is speaking about that that's what kind of reflects to that typical variability quarter to quarter.

Our next question comes from Brito Borough of Cowen. Please go ahead.

Good afternoon, guys. Thanks for taking the question.

Good to see you at the conference this past weekend.

I wanted to ask about your data that you presented on the partial serum bile acids.

Responders.

It was pretty intriguing as to what it might mean for.

Potential liver survival across the colon static conditions.

Can you can you talk to what.

Right.

Okay.

What it might mean for clinicians and their especially the U S U S physicians and their perspective.

Bill.

Ah pruritus drug versus building.

Building as a drug that could prolong liver survival.

So the hiring to be a pleasure to see you is while you were chopping in and out a little bit, but I think what you're what you were saying is some of the data that we presented on native liver survival with building <unk>, what does that kind of mean to U S prescribers and how do you think it will.

How do we do it right.

So you are saying.

Yeah, especially given the partial partial responder class as part of that dataset.

Sure.

So sorry, I think I think what's interesting is it's the same types of patients around the world. It's the same phase III data. There is some different utility indifferent to different geographies and what we find is when physicians really understand that <unk> has the potential not only to improve their symptoms right, but also.

To help with.

With preserving livers overtimes.

That's where they get really compelled to do things. So I think what we are excited about the data that was that was presented this past weekend, particularly if you look at the piece of two patients.

Really no difference between the two.

The full responders and partial responders.

And remember these responders at responder definition. This is what we've created with the partial responders yesterday, it's a pretty strict definition. The partial responder definition expands that definition. The net of that is it doesn't really matter, if you're a partial responder or a full full responder you seemed to do pretty well.

In P fit with your data on liver survival based on the data presented this past weekend.

Got it and is that is that something that you can take to U S. D. A to change label language I mean, it was a pretty compelling presentation.

Okay.

Yes. It was thank you for the compliment it was a compelling presentation I think as John has said in the prepared comments. This is just the first of other data sets that we're creating and working on so as these datasets mature I think there'll be a time, but we will get into a dialogue with regulatory authorities.

Our reaction to the data we will take it from there.

Got it thanks for taking the question.

Thank you you too.

Our next question comes from Seamus Fernandez of Guggenheim. Please go ahead.

Great. Thanks for the question. So Ron one quick one question for you is just how you see the opportunity in Europe in particular as you.

<unk> bring on the allergy all indication.

It seems like there is an opportunity with established reimbursement to capitalize on that market and potentially.

Secure reimbursement prior to the.

The competitor, who maybe it is.

It's going to be in the market a little bit earlier with the indication, but not necessarily reimbursement and the second question is just in terms of the pipeline.

The earlier stage pipeline can you guys update us on how.

You're planning to kind of progressed products in those markets.

In particular and.

When we're likely to see data.

And what you're most excited about in the earlier stage pipeline. Thanks.

Alright, Thank you Jamie actually maybe the first question in regards to Europe I'll, let Pamela comment first and then I'll talk a little bit about how we see the pipeline evolving so Pamela sorry, Hi Chinas.

The first thing I would say is we have a lot of experience with payers in Europe and are pleased with the high assessments clinical assessments that we've been given and just have experienced when we sort of know the questions that there'll be asking so as we head into allergy. All we think this certainly gives us a good advantage in terms of being able to click.

Submit the reimbursement dossiers to get the type of high clinical ratings, that's neat needed to secure favorable pricing and reimbursement and we already have the contracts in place with many of these large payers and so we expect that process to go quite well and quite smoothly.

And I would just add Seamus if you kind of think about these European countries place by place, we're going there with phase III data with the assert data, which looks good which looks really well we received as panelists are great indications and good ratings with the <unk> data, we already have contracts in place by that.

Time in most countries, we have a <unk>.

Salesforce in place it should be up to go pretty quickly. There. So we look forward to that and then as it relates to the early stage pipeline.

We're excited about it these are real real drugs <unk> 907, the worlds first and only systemic <unk> inhibitor <unk>.

<unk> three <unk> is the world's first and only oral <unk> inhibitor <unk> hundred 90, <unk> will be going into a phase II study.

83 for two will be going into a phase one study and we anticipate having some data next year and so we're pretty excited about is these drug to long ago were just ideas beyond this team have done a great job in advancing these products, we're coming into some studies that are really going to tell us an awful lot about the potential for these.

New medicines.

Our next question comes from Tim Lugo of William Blair. Please go ahead.

Alright. Thank you for taking my question and I guess, just expanding on the liver survival data I believe the presenter mentioned that I guess I'll quote was only time will tell before we know that.

This truly.

A disease modifying therapy and it sounds like you're on it's kind of working on more data around that can you just maybe expand upon that timeframe.

I agree with everything is pointing in that direction, but maybe whats kind of a timeframe before the community. It comes around to seeing Beauvais is truly disease modifying therapy versus maybe some of the community just viewing that as.

Symptomatic therapy can you just maybe give us some vessel one years this into your timeframe, what what do you believe.

Yeah, I think thanks for the question Tim I think this is always just classic question. When you were at these scientific meetings at longer result.

It is always better, but I think in this case.

The question the real question is yes.

Will you reverse liver disease, right, which is a very high bar.

I don't know if you.

If we or anybody will be able to show that over a long timeframe. So that's sort of the sort of the ultimate right.

I think now that we have data that goes three years.

More data over time with many of the community members believes that this is this is really important data that we are in fact, we should we've given data to show that we improved native liver survival and I know that the presenter in this case it was a strong believer in that as well. So we believe we're modifying the disease right and that's what's most important.

To be able to say youre reversing the disease I don't know if anybody's going to be doing that's going to be a bar that's very high.

Completely understood.

I guess, just more commercially you're talking it sounds like 77 patients or pending reimbursement.

Yes, I know, we're still early into the launch but has there been any leakage of those patients kind of since the beginning of a launch or should we just assume that those 77 patients will eventually go on to reimbursed therapy over.

A certain number of months.

Yeah.

Yeah, you can assume that those patients will go onto therapy. There is there's been no leak with no leakage those patients are literally in countries, where we don't yet have final reimbursement and our history to date has been that those patients in the countries when we get reimbursement have transitioned.

Understood. Thank you for the clarity.

Thank you Tim.

Our next question comes from Andreas <unk> of Wedbush Securities. Please go ahead.

Hey, good afternoon, and congrats on the progress during the quarter.

So we're building in <unk>, you mentioned patient weight is normalizing.

Still seeing that.

I guess are being prescribed more in younger patients.

Where do you see the biggest impact of the recent growth coming from.

Follow up.

Yeah.

So what we're seeing is with it with a patient waits if I understand your question correctly, it's where we're seeing younger patients and older patients that we're seeing a good variability of patients coming onto Bill Weil.

And because the overall number of build a patients is increasing you know there's sort of the impact of the individual fluctuations will subside over time and overall the number of patients of revenue will increase.

Okay great.

With the strong gold standard data.

Our <unk> syndrome.

Building differentiating from competitors launched in the U S and EU is it under one year old population there.

Good meaningful safety difference on diarrhea encourage switching.

Well I think first of all Andreas first time that you see phase three data randomized placebo controlled data if I take the <unk>.

The action of the both the U S and the international community at the ASR. The liver meeting this past week and they are pretty excited to have that so it's not one thing it's a range of things. It's the fact that that.

There are both mutation types in this database, it's the fact that it is.

A wider range of patients. It's the fact that the effects, we're seeing very early and that they were sustained at cross over time, and then to your point on the Tolerability. We're just absolutely delighted about the diarrhea rates.

Five nine.

In the placebo group at $11 four in the <unk> group and that was consistent with what we saw with the <unk> patients as well right. So yeah. If you look at that totality of the database I don't think its one thing. It's multiple things that are drive then you throw on top of that just the drug itself.

Hi, Andrew.

When we think when we talk to the physicians. The fact that it's once a day always once it's a low dose. It's a capsule that can either be taken as a capsule or or or mixed with food or mixed with water you put that package together and I think that's what's exciting both the U S physicians in the international positions.

Okay, great Yeah, it's exciting and congrats again on the progress.

Thank you Andreas.

Our next question comes from Ed Arce of H C. Wainwright. Please go ahead.

Yes.

Hi, Good afternoon, everyone. This is Thomas Yip asking a couple of questions for Ed. Thank you for taking my questions. So a couple from us.

Assuming <unk> approval for a J REIT in U S and EU.

What would you highlight the most important aspects in our fourth potential commercial launch.

Those two areas.

It was a little bit look what I said before previously TV I think its phase III data unequivocal data and just the breadth and depth of that data across different patient types, there's sort of different mutations.

A wide range of broad range of patients right sleep, great sustained effect. So I think that's what we'll speak about it and then just the implicit qualities of the drug itself always once a day always low dose easy easy to give with food urban capsule or in the liquid.

At a very reasonable Tolerability profile, we think that is a best in class profile and that's what is going to be attractive.

Understood and then perhaps a one question for Bill there is for sure.

Most of your yes, your point that will completely road.

How should investors look at the market opportunity as you mentioned this.

Much larger market compared to your peers are.

That was true even come Brian .

Can you outline some major differences that you anticipate and commercial strategy in beverage for sure versus the other two indications.

Okay.

Well, that's the beauty of our business model.

Thomas when you really think about it it's the same doctors that prescribe for <unk> for allergy deal for biliary Atresia, we built out a commercial structure in the U S. Europe .

That covers that.

That audience and covers it very well so we're not going to require much incremental resources to get up these customers and so as we get to bill rate trees, which as you said, it's the biggest opportunity.

We think that that's really becomes a game changer for us right that can really accelerate our business.

Got it.

For example, it's a kind of a <unk>.

<unk> and looking forward to the progress and I'll, let drew record for Repowering.

We have reached the end of our Q&A session I will now turn the call over to Ron for closing remarks.

Great. Thank you operator, and thank you all for attending today's conference call.

I'm really proud of our organization's ability to deliver and execute as planned and I. Thank each and every one of our employees for their commitment and drive and innovation.

We continue to keep you updated as we advance <unk> mission to provide hope to patients and families impacted by these devastating liver diseases.

You all for your continued support.

This concludes today's conference call you may disconnect. Your lines. Thank you for participating and have a pleasant day.

[music].

Okay.

[music].

Okay.

Okay.

Okay.

Okay.

Yeah.

Yeah.

Yeah.

Okay.

Okay.

Yeah.

[music].